Skip to main content

Table 3 DaT-SPECT quantitative metrics

From: Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial

 

DaT-SPECT screened

DaT-SPECT “abnormal”

DaT-SPECT “normal”

Quantifiable, N

389

377

12

Striatal binding ratio

 Whole striatum

1.37 ± 0.37

1.35 ± 0.35

2.03 ± 0.54

 Whole putamen

1.33 ± 0.41

1.30 ± 0.37

2.27 ± 0.61

 Whole caudate

1.40 ± 0.37

1.39 ± 0.36

1.79 ± 0.49

 Most affected putamen

1.19 ± 0.39

1.16 ± 0.33

2.21 ± 0.61

 Demographically indexed most affected putamen

0.25 ± 0.08

0.24 ± 0.07

0.46 ± 0.11

Abnormal whole striatum uptake, %

99.4

100

83

Abnormal whole putamen uptake, %

99.4

98.7

75

Abnormal whole caudate uptake, %

100

100

100

Striatal asymmetry index

4.30 ± 2.85

4.40 ± 2.84

1.17 ± 0.70

Abnormal striatal asymmetry index, %

0

0.5

0

  1. Data are mean ± SD unless otherwise noted
  2. DaT-SPECT dopamine transporter single-photon emission computed tomography